Edward Garland Mccormick, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 227 Maple Ave, Oak Hill, WV 25901 Phone: 304-469-3615 Fax: 304-469-3652 |
Dr. Barry Alan Stowers, D.C. Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 111 Lewis St, Oak Hill, WV 25901 Phone: 304-465-0561 Fax: 304-465-0562 |
Pinnacle Chiropractic Health & Wellness Pllc Chiropractor Medicare: Medicare Enrolled Practice Location: 325 Jones Ave, Oak Hill, WV 25901 Phone: 304-465-4325 Fax: 304-465-4326 |
Dr. Christopher Blake Flint, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 325 Jones Ave, Oak Hill, WV 25901 Phone: 304-465-4325 Fax: 304-465-4326 |
Kominsky Chiropractic Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 227 Maple Ave, Oak Hill, WV 25901 Phone: 304-469-3615 Fax: 304-469-3652 |
News Archive
A review by RCSI University of Medicine and Health Sciences in collaboration with the HSE National Quality Improvement Team has found that quality improvement (QI) studies in Ireland over a five-year period conformed to high reporting standards and enhanced multiple elements of healthcare quality.
MicroBiome Therapeutics LLC, a biotechnology company developing pharmaceutical and medical food products that shift the human microbiome in specific ways for improved health, today reported publication of a case report suggesting a potentially important new application for its lead product, NM504. NM504 is in clinical development to promote healthy blood glucose levels and metabolic fitness in prediabetic and diabetic populations.
As Americans increasingly seek a "quick fix" to physical and mental ailments, psychoanalysts can be caught in the crossfire of a debate about the potential benefits and drawbacks of including medication in their treatment plans.
A review published in The Lancet Oncology reveals significant shortfalls in radiotherapy equipment and manpower across Europe.
EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing.
› Verified 9 days ago